MRC Clinical Trials Unit at UCL
90 High Holborn
Clinical trials are research studies involving patients, which compare a new or different type of treatment with the best treatment currently available (if there is one). Some clinical trials look at possible ways to prevent illnesses, for example by testing new vaccines. No matter how promising a new drug or treatment may appear during tests in a laboratory, it must go through clinical trials before its benefits and risks can really be known. Trials aim to find out if treatments are safe (what side effects they have), and if they work better than the treatment used currently.
Clinical trials are the most reliable and best way of testing treatments. A new treatment is not always better, and can sometimes be worse than existing treatments. Trials are therefore very important to find out whether one treatment is safer and more effective than another, or sometimes to find out if it is just as good.
New treatments usually have to go through a series of clinical trial phases to test whether they are safe and effective. New drugs go through a number of different phases of a trial:
Randomised controlled trials (RCTs) are a type of clinical trial. RCTs, like STAMPEDE, aim to make a fair comparison between a new treatment and the existing treatment, or between two (or more) existing treatments, to see which one works best.
A controlled trial compares two or more groups of people: one or more experimental group(s) who receive a new treatment, and a control group, who receive the current standard treatment (which might be the best existing treatment, no treatment or a placebo). Information from the follow-up of the control group allows the researchers to see whether the new treatment(s) they are testing are any more or less effective than the existing treatment.
The decision about which treatment each participant in a randomised controlled trial receives is made at random – based on chance, rather than decided by the doctor or participant. This process is called randomisation.
Randomisation ensures that the two (or more) groups of people in a trial are as similar as possible, except for the treatment they receive. This is important because it means that researchers can be sure that any differences in outcomes between the groups are therefore only due to the treatment received.
Randomisation is the best way of ensuring that the results of trials are not biased by the way participants in each group are selected. For example, if a doctor chose which treatment a patient should receive as part of a trial, she or he might give the new treatment to sicker patients, or to younger patients. This would make the results of a trial unreliable, as it could exaggerate or hide the effects of the treatment.
Randomised controlled trials are the most reliable way to compare treatments.
A lot of care is taken to ensure that clinical trials are as safe as possible. Some of the things that go into making a trial safe are detailed as follows;
Independent Scientific Review
All trials conducted at the MRC Clinical Trials Unit at UCL are scientifically reviewed before the trial can start. The plan for the trial (called the protocol) is sent to a number of independent scientists for comment. The protocol may also be sent to patients, to ask for their comments. Both patients and researchers must be independent of the trial.
All our trials have to be examined and approved by an ethics committee before they can start, to make sure the planned research is ethical and as safe as possible. This committee usually includes members of the public, researchers and health care professionals. Any changes that are made to the trial protocol while the trial is running also have to be examined and approved by the ethics committee. Researchers must tell the ethics committee if people experience unexpected and serious side effects during the trial.
Data Monitoring Committees
Most trials have a data monitoring committee that looks at how the trial is progressing. The people on the data monitoring committee must be independent of the trial. An independent group of people like this is able to look at the interim results of a trial and decide if a clear result has been reached. Their aim is to ensure that the trial is safe. If the data monitoring committee sees any information or data to indicate that a trial should not continue, perhaps because people are experiencing serious side effects that were not expected, this committee can recommend that a trial is stopped.
National and International Guidelines
There are guidelines to ensure that trials are run properly. European Law agreed in 2004 means that all organisations that run trials must ensure there are arrangements in place in case people are harmed during a trial of a drug. You can read more on this in the guidelines from the Department of Health on Good Clinical Practice (GCP) in non-commercial trials. The Research Governance Framework developed by the Department of Health sets out standards of good practice in the conduct of health research. Ethics committees check these arrangements are in place when they make decisions about whether to agree that a trial can go ahead.
Before a participant joins a trial, the researcher must explain the trial and get the person’s agreement to take part. The researcher must explain:
All participants should receive a patient information sheet explaining these things. Participants are asked to sign a form giving informed consent to take part in a trial. Informed consent means that participants have been given the important facts about a trial, understand them and have decided to take part in the trial of their own free will. Participants can change their mind after signing the informed consent form, and can withdraw from a trial at any stage.
Confidentiality of patient data is very important in clinical trials. In a trial, all medical records are confidential. This information is kept securely, and only a very limited number of people have access to it. Participants’ names, or details that could help others identify individual participants, are not used in any reports about the trial.
MRC Clinical Trials Unit at UCL
90 High Holborn
Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy
See the latest News in STAMPEDE through the link to the right.